NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY. (17th June 2021)

• Record Type: Journal Article
• Authors: Ansell, S. M.; Bröckelmann, P. J.; von Keudell, G.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Collins, G. P.; Cohen, J. B.; De Boer, J. P.; Kuruvilla, J.; Savage, K. J.; Trneny, M.; Provencio, M.; Jaeger, U.; Willenbacher, W.; Swanink, R.; Sacchi, M.; Shipp, M. A.; Engert, A.; Armand, P.
• Is Part Of: Hematological oncology. Volume 39(2021)Supplement 2
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-06-17
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.70_2880
• Languages: English
• ISSNs: 0278-0232